News >

Frontline Pembrolizumab Improves Survival at Lower PD-L1 Threshold

Jason M. Broderick @jasoncology
Published: Monday, Apr 09, 2018

Tony Mok, MD

Tony Mok, MD
Single-agent treatment with the PD-1 inhibitor pembrolizumab (Keytruda) improved overall survival (OS) versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a PD-L1 expression level ≥1%.

The approval was based on part 2 of cohort G in the KEYNOTE-021 trial, which showed that the frontline combination of pembrolizumab, pemetrexed, and carboplatin reduced the risk of progression or death compared with chemotherapy alone for patients with advanced nonsquamous NSCLC. Updated results for the study were presented at the 2017 ESMO Congress.2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication
x